Comparing diagnostic tests on benefit-risk

Journal of Biopharmaceutical Statistics

Volumn 26, Issue 6, 2016, Pages 1083-1097

  Pennello, Gene ^a   Pantoja Galicia, Norberto ^a   Evans, Scott ^b  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Clinical utility; cost benefit ratio; decision theory; diagnostic yield; relative net benefit; risk threshold; weighted accuracy

Indexed keywords

ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION THEORY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; PREVALENCE; RISK ASSESSMENT;

COLONOSCOPY; COLORECTAL NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; PREVALENCE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84990987576     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2016.1226335     Document Type: Article

References (22)

1. Baker, S. G., (2009). Putting risk into perspective:Relative utility curves. Journal of the National Cancer Institute 101:1538–1542.
2. Baker, S. G., Cook, N. R., Andrew Vickers, A., Kramer, B. S., (2009). Using relative utility curves to evaluate risk prediction. Journal of the Royal Statistical Society A 172(4):729–748.
3. Baker, S. G., Kramer, B. S., (2012). Evaluating a new marker for risk prediction:Decision analysis to the rescue. Discovery Medicine 14(76):181–188.
4. Baker, S. G., Van Calster, B., Steyerberg, E. W., (2012). Evaluating a new marker for risk prediction using the test tradeoff:An update. The International Journal of Biostatistics 8(1):Article 5.
5. Biggerstaff, B. J., (2000). Comparing diagnostic tests:A simple graphic using likelihood ratios. Statistics in Medicine 19:649–663.
6. Bossuyt, P. M., Lijmer, J. G., Mol, B. W., (2000). Randomised comparisons of medical tests:Sometimes invalid, not always efficient. Lancet 356:1844–1847.
7. Cook, N. R., (2007). Use and misuse of the receiver operating characteristics curve in risk prediction. Circulation 115(7):928–935.
8. Deneef, P., Kent D., (1993). Using treatment-tradeoff preferences to select diagnostic strategies:Linking the ROC curve to threshold analysis. Medical Decision Making 13:126–132.
9. Evans, S. R., Pennello, G., Pantoja-Galicia, N., Jiang, H., Hujer, A. M., Hujer, K. M., Manca, C., Hill, C., Jacobs, M. R., Chen, L., Patel, R., Kreiswirth, B. N., Bonomo, R. A., The Antibacterial Resistance Leadership Group (ARLG). (2016). Benefit-risk evaluation for diagnostics:A framework (BED-FRAME). Clinical Infectious Diseases 63(6):812–817. doi:10.1093/cid/ciw329.
10. Food and Drug Administration (2007). Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests:Guidance for Industry and FDA Reviewers (released March 13, 2007). http://www.fda.gov/RegulatoryInformation/Guidances/ucm071148.htm (accessed September 2016).
11. Gail, M. H., Pfeiffer, R. M., (2005). On criteria for evaluating models of absolute risk. Biostatistics 6:227–239.
12. Hoering, A., Leblanc, M., Crowley, J., (2008). Randomized Phase III clinical trial designs for targeted agents. Clinical Cancer Research 14(14):4358–4367. [PubMed:18628448]
13. McIntosh, M. W., Pepe, M. S., (2002). Combining several screening tests:Optimality of the risk score. Biometrics 58:657–664.
14. Metz, C. E., (1978). Basic principles of ROC analysis. Seminars in Nuclear Medicine 8(4):283–298.
15. Pauker, S. G., Kassirer, J. P., (1975).Therapeutic decision making:A cost-benefit analysis. New England Journal Medicine 293:229–234.
16. Pepe, M. S., Janes, H., Li, C. I., Bossuyt, P. M., Feng, Z., Hilden J., (2016). Early-phase studies of biomarkers:What target sensitivity and specificity values might confer clinical utility? Clinical Chemistry 62:737–742.
17. Pepe, M. S., Janes, H., Longton, G., Leisenring, W., Newcomb, P., (2004). Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology 159(9):882–890.
18. Simon, R., (2010) Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Personalized Medicine 7(1):33–47. doi:10.2217/pme.09.49.
19. Tsalik, E. L., Li, Y., Hudson, L. L., Chu, V. H., Himmel, T., Limkakeng, A. T., Katz, J. N., Glickman, S. W., McClain, M. T., Welty-Wolf, K. E., Fowler, V. G., Ginsburg, G. S., Woods, C. W., Reed, S. D., (2016). Potential cost-effectiveness of early identification of hospital-acquired infection in critically Ill patients. Annals of the American Thoracic Society 13(3):401–413.
20. Rutter, C. M., Johnson, E., Miglioretti, D. L., Mandelson, M. T., Inadomi, J., Buist, D. S.M, (2012). Adverse events after screening and follow-up colonoscopy. Cancer Causes Control 23:289–296.
21. Vickers, A. J., Elkin, E. B., (2006). Decision curve analysis:A novel method for evaluating prediction models. Medical Decision Making 26:565–574.
22. Zweig, M. H., Campbell, G., (1993). Receiver-operating characteristic (ROC) plots:A fundamental evaluation tool in clinical medicine. Clinical Chemistry 39(4):561–577.